Biocept
is dedicated to improving the outcomes for cancer patients by developing
innovative diagnostic solutions. The company’s primary diagnostic tool, known
as a liquid biopsy, allows patients and doctors to gather a host of important
information from a simple blood test. Using its patented methodology, the
company allows for the isolation of rare cells – such as circulating tumor
cells, which are a type of seed that can promote additional tumor growth –
without the need for a tissue sample.
The
company’s liquid biopsy test is intended to assist physicians in understanding
the status of a patient’s disease while contributing to the development of
current and future therapy plans. Though treatments for metastic cancer, or
cancer that is spread from one organ to another organ in a different area of
the body, have advanced in recent years, timely diagnosis of the disease
remains critical for the patient’s overall odds of survival. According to a
report from the American Cancer Society, the chances of surviving metastic
cancer are greatly increased if it is diagnosed in its early stages.
While
doctors have already used the company’s biomarker technology to successfully
assist thousands of patients, Biocept is continuing to study the diagnostic
potential of its blood-based tools. The company recently completed a trial that
showed the effectiveness of its proprietary technology in determining hormonal
status in metastatic breast cancer patients.
“We
are encouraged that the results of this study further support the validity of
Biocept’s liquid biopsy in the continuous monitoring and treatment of breast
cancer,” said Veena Singh, M.D., Senior Vice President and Senior Medical
Director of Biocept.
Comments
from doctors involved in the recent study indicated that the company’s
diagnostic tool could have significant implications on the treatment of cancer
patients for whom tissue samples are not feasible.
Biocept
currently offers CLIA validated tests for breast, lung and gastric cancers, and
the company plans to conduct additional studies for colorectal, prostate and
other solid tumors using its proprietary platforms in the future.
For
more information, visit www.biocept.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
